Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.69 |
| ▸ | TP53 | P04637 | 6/20 | 0.69 |
| ▸ | THRB | P10828 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1007605 | 0.91 | POLB (0.63) | MAPTTP53LMNAPOLBCYP1A2 | |
| SCHEMBL1007066 | 0.89 | SMN1; SMN2 (0.63) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL1007250 | 0.86 | MAPT (0.52) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL8000803 | 0.86 | MAPT (0.52) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL1006951 | 0.86 | MAPT (0.52) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL1007964 | 0.86 | MAPT (0.52) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL1007958 | 0.85 | MAPT (0.50) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL1008079 | 0.85 | MAPT (0.50) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL1006664 | 0.84 | MAPT (0.56) | MAPTTP53THRBLMNAPOLB | |
| SCHEMBL1900171 | 0.82 | SMN1; SMN2 (0.75) | MAPTTP53THRBLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009119088-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | MAPT 4623/4885TP53 3973/4885THRB 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.